FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1754313006> ?p ?o ?g. }

• W1754313006 endingPage "2" @default.
• W1754313006 startingPage "710" @default.
• W1754313006 abstract "Several studies comparing different intensities of oral anticoagulant treatment have clearly shown a relationship between bleeding complications and prolongation of prothrombin time. In the early '50s, de Takats suggested that low-dose oral anticoagulants might be as effective as higher doses in preventing thrombosis, at a lower risk of bleeding. This review article examines the potential of low dose warfarin therapy.The authors have been working in this field, contributing original papers. In addition, the material examined in this article includes articles published in the journals covered by the Science Citation Index and MedLine.The hypothesis that low-dose oral anticoagulants can be effective in preventing thrombosis was first proven by experiments in animal models, and showed that a prothrombin time ratio as low as 1.14 using rabbit brain thromboplastin was still able to confer some inhibition of experimental thrombosis. Low-dose or very low-dose warfarin were subsequently demonstrated to be effective in patients with morbid obesity and decreased antithrombin III functional and antigenic levels, in patients with indwelling catheters, in patients undergoing gynecological surgery, as well as in patients with stage IV breast cancer. Low-dose warfarin is also effective in the prevention of embolic strokes in patients with non-rheumatic atrial fibrillation. However, older patients (> 75 years), who have a very high risk of bleeding, might be safer taking a very low dose of warfarin (i.e., a daily dose of 1-1.25 mg). Moreover, after a period of run-in, a fixed, very low-dose warfarin schedule does not need further laboratory control, which is a factor that could contribute to the full acceptance of treatment by patients and could stimulate a broader prescription of warfarin for the primary prevention of stroke in older patients with nonrheumatic atrial fibrillation. Therefore, we have organized a multicenter clinical trial in which 1000 patients with non-rheumatic atrial fibrillation will be randomized to receive either a fixed mini-dose of warfarin or a standard dose. Positive results might permit the treatment of most older patients with non-rheumatic atrial fibrillation, creating a benefit for the community as a consequence of its effective prevention of disabling strokes." @default.
• W1754313006 created "2016-06-24" @default.
• W1754313006 creator A5011151808 @default.
• W1754313006 creator A5028187618 @default.
• W1754313006 creator A5051451313 @default.
• W1754313006 creator A5068778127 @default.
• W1754313006 creator A5083702193 @default.
• W1754313006 date "1998-03-21" @default.
• W1754313006 modified "2023-09-23" @default.
• W1754313006 title "Low intensity warfarin therapy." @default.
• W1754313006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9499673" @default.
• W1754313006 hasPublicationYear "1998" @default.
• W1754313006 type Work @default.
• W1754313006 sameAs 1754313006 @default.
• W1754313006 citedByCount "1" @default.
• W1754313006 crossrefType "journal-article" @default.
• W1754313006 hasAuthorship W1754313006A5011151808 @default.
• W1754313006 hasAuthorship W1754313006A5028187618 @default.
• W1754313006 hasAuthorship W1754313006A5051451313 @default.
• W1754313006 hasAuthorship W1754313006A5068778127 @default.
• W1754313006 hasAuthorship W1754313006A5083702193 @default.
• W1754313006 hasConcept C126322002 @default.
• W1754313006 hasConcept C141071460 @default.
• W1754313006 hasConcept C19831878 @default.
• W1754313006 hasConcept C2776301958 @default.
• W1754313006 hasConcept C2779161974 @default.
• W1754313006 hasConcept C2780035454 @default.
• W1754313006 hasConcept C2780434524 @default.
• W1754313006 hasConcept C2780868729 @default.
• W1754313006 hasConcept C42219234 @default.
• W1754313006 hasConcept C71924100 @default.
• W1754313006 hasConcept C98274493 @default.
• W1754313006 hasConceptScore W1754313006C126322002 @default.
• W1754313006 hasConceptScore W1754313006C141071460 @default.
• W1754313006 hasConceptScore W1754313006C19831878 @default.
• W1754313006 hasConceptScore W1754313006C2776301958 @default.
• W1754313006 hasConceptScore W1754313006C2779161974 @default.
• W1754313006 hasConceptScore W1754313006C2780035454 @default.
• W1754313006 hasConceptScore W1754313006C2780434524 @default.
• W1754313006 hasConceptScore W1754313006C2780868729 @default.
• W1754313006 hasConceptScore W1754313006C42219234 @default.
• W1754313006 hasConceptScore W1754313006C71924100 @default.
• W1754313006 hasConceptScore W1754313006C98274493 @default.
• W1754313006 hasIssue "6" @default.
• W1754313006 hasLocation W17543130061 @default.
• W1754313006 hasOpenAccess W1754313006 @default.
• W1754313006 hasPrimaryLocation W17543130061 @default.
• W1754313006 hasRelatedWork W1964666267 @default.
• W1754313006 hasRelatedWork W2008405473 @default.
• W1754313006 hasRelatedWork W2011524758 @default.
• W1754313006 hasRelatedWork W2115622226 @default.
• W1754313006 hasRelatedWork W2569305763 @default.
• W1754313006 hasRelatedWork W2583701874 @default.
• W1754313006 hasRelatedWork W2681806790 @default.
• W1754313006 hasRelatedWork W2889182102 @default.
• W1754313006 hasRelatedWork W3214976259 @default.
• W1754313006 hasRelatedWork W4241944220 @default.
• W1754313006 hasVolume "82" @default.
• W1754313006 isParatext "false" @default.
• W1754313006 isRetracted "false" @default.
• W1754313006 magId "1754313006" @default.
• W1754313006 workType "article" @default.